BSE List Price : ₹83.00

NSE List Price : ₹83.00

subscription

Category	Times
QIBs	1.62x
HNIs	14.05x
Retail	7.06x
Total : 7.27x

IPO Market Lot(s) Distribution

Application	Lot Size	Shares	Amount
Retail Minimum	1	189	₹14,931
Retail Maximum	13	2,457	₹194,103
S-HNI Minimum	14	2,646	₹209,034
S-HNI Maximum	66	12,474	₹985,446
B-HNI Minimum	67	12,663	₹1,000,377

About the Company

Gaudium IVF, established in March 2015, is among the prominent providers of In Vitro Fertilization (IVF) treatment services for women throughout India. The company currently operates across more than 30 locations, comprising seven hub centres and twenty-eight spoke centres. It also serves patients from several international markets, including Canada, the United Kingdom, the United States, Kenya, South Africa, and Oman.
The company provides a wide range of fertility solutions, including In Vitro Fertilisation (IVF), Intracytoplasmic Sperm Injection (ICSI), Intrauterine Insemination (IUI), and ovulation induction. These services are designed to address fertility concerns in both men and women. In addition, the company offers specialised care for conditions such as PCOD/PCOS, endometriosis, and supports women with complicated fertility-related pregnancy cases. Gaudium IVF also delivers male infertility treatments, including specialised and advanced sperm retrieval techniques.

Company Financial Report

_{Amount ₹ in Crores}

Period Ended	Revenue	Expense	PAT	Assets
2023	₹44.26	₹25.95	₹13.53	₹36.63
2024	₹48.15	₹31.52	₹10.32	₹51.01
2025	₹70.96	₹45.54	₹19.13	₹88.51
Sep 2025	₹49.75	₹32.97	₹12.51	₹106.62

Company Promoter

Dr. Manika Khanna

Dr. Peeyush Khanna

Vishad Khanna

Know before investing

• • Strengths

  Patient-Focused Pricing Strategy: The Company follows a package-based pricing model, combined service offerings, and easy installment plans to make fertility treatments accessible to middle-income patients. Its clear and transparent pricing structure, along with flexible payment options, helps build patient confidence and supports growth in its customer base.

  Emphasis on Medical Tourism: Taking advantage of India’s lower treatment costs, the Company draws international patients by offering multilingual assistance, personalised concierge services, and international partnerships. Its strategic alliances with overseas agencies and hospitals help ensure a consistent inflow of patients from abroad.

• • Risks

  Operational and Clinical Risks in Fertility Services: The Company is engaged in fertility procedures such as IVF, IUI, ICSI, and egg freezing, which carry inherent medical, operational, legal, and reputational risks. Any inability to uphold high standards of healthcare quality may negatively impact its reputation, future business opportunities, and financial performance.

  Reliance on a Small Team of Embryologists: The Company’s activities across its seven centres are significantly dependent on a team of five embryologists. Any failure to retain existing specialists or recruit qualified embryologists may adversely affect its operations, financial health, and future growth prospects.

Objects of the Issue & Utilisation of proceeds

Funding capital expenditure towards establishment of New IVF Centers of the Company.
Repayment/pre-payment, in full or in part, of certain outstanding loans availed by our Company; and.
General Corporate Purpose.

Company  Address

Gaudium IVF & Women’s Health Ltd.
B1/51,
Janak Puri,
B-1,
New Delhi, New Delhi, 110058
Phone: 011-4885 8585
Email: compliance@gaudiumivfcentre.com
Website: https://www.gaudiumivfcentre.com/

IPO Registrar

Bigshare Services Pvt. Ltd.
Phone: +91-22-6263 8200
Email: ipo@bigshareonline.com
Website: https://ipo.bigshareonline.com/IPO_Status.html

IPO Review

May Apply